Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 161 participants.

Also called NCT01955707

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 161 participants (enrolled count) (from the registry)
Sponsor
  • Biogen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01955707
Other papers using this trial's data
  • Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial The Lancet. Neurology, 2017-03 DOI, PubMed 28229893

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Germany, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01955707. Randomized; double masking; primary purpose treatment. Start 2014-01 (registry gives no type); primary completion 2015-02 (actual). Results posted on 2016-07-01.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke
Acronym
ACTION
Condition
Acute Ischemic Stroke
Intervention (Drug)
natalizumab
Intervention (Drug)
Placebo
Lead sponsor
Biogen (class: industry)

Record details

Record id
cardio:ct-nct01955707
Content hash
8a0d22281f70e1ce9c9d2ea5c16e2fe6777102ef7f27f492de5ec5f63f218d63